Title |
Cost-Effectiveness of Point-of-Care C-Reactive Protein Tests for Respiratory Tract Infection in Primary Care in England
|
---|---|
Published in |
Advances in Therapy, January 2015
|
DOI | 10.1007/s12325-015-0180-x |
Pubmed ID | |
Authors |
Rachael Hunter |
Abstract |
Despite recommendations that general practitioners (GPs) delay antibiotic prescribing for respiratory tract infections (RTIs), antibiotic prescriptions in primary care in England increased by 4.1% from 2010 to 2013. C-reactive protein (CRP) point-of-care tests (POCT), for example, the Afinion™ Analyzer (Alere Ltd, Stockport, UK) device, are widely used in several countries in the European Union. Studies suggest that CRP POCT use, either alone or in combination with communication training, reduces antibiotic prescribing and improves quality of life for patients presenting with RTI symptoms. The aim of this study is to evaluate the cost-effectiveness of CRP POCT for RTIs in primary care in England over 3 years for three different strategies of care compared to standard practice. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 17% |
Unknown | 5 | 83% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 67% |
Scientists | 1 | 17% |
Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Malaysia | 1 | <1% |
United Kingdom | 1 | <1% |
Unknown | 139 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 29 | 21% |
Student > Master | 26 | 18% |
Other | 17 | 12% |
Student > Ph. D. Student | 11 | 8% |
Student > Bachelor | 9 | 6% |
Other | 25 | 18% |
Unknown | 24 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 54 | 38% |
Nursing and Health Professions | 10 | 7% |
Biochemistry, Genetics and Molecular Biology | 7 | 5% |
Social Sciences | 6 | 4% |
Immunology and Microbiology | 5 | 4% |
Other | 28 | 20% |
Unknown | 31 | 22% |